JO3044B1 - نظام تناول جرعة لمنبه مستقبل s1p - Google Patents
نظام تناول جرعة لمنبه مستقبل s1pInfo
- Publication number
- JO3044B1 JO3044B1 JOP/2009/0495A JOP20090495A JO3044B1 JO 3044 B1 JO3044 B1 JO 3044B1 JO P20090495 A JOP20090495 A JO P20090495A JO 3044 B1 JO3044 B1 JO 3044B1
- Authority
- JO
- Jordan
- Prior art keywords
- dosage regimen
- receptor agonist
- dosage
- daily dosage
- regimen
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
معدلات او منبهات مستقبل S1P يتم تعاطيها باتباع نظام تناول الجرعة والذي بمقتضاه خلال ايام المعالجة المبدئية تكون الجرعة اليومية أقل من الجرعة اليومية القياسية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967308P | 2008-12-22 | 2008-12-22 | |
EP09167209 | 2009-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3044B1 true JO3044B1 (ar) | 2016-09-05 |
Family
ID=41435196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0495A JO3044B1 (ar) | 2008-12-22 | 2009-12-21 | نظام تناول جرعة لمنبه مستقبل s1p |
Country Status (35)
Country | Link |
---|---|
US (2) | US8492441B2 (ar) |
EP (1) | EP2379069B1 (ar) |
JP (2) | JP5657565B2 (ar) |
KR (1) | KR101660555B1 (ar) |
CN (2) | CN102264363A (ar) |
AR (1) | AR074825A1 (ar) |
AU (1) | AU2009331582B2 (ar) |
BR (1) | BRPI0923213A2 (ar) |
CA (3) | CA3105857C (ar) |
CY (2) | CY1116321T1 (ar) |
DK (1) | DK2379069T3 (ar) |
ES (1) | ES2538413T3 (ar) |
FR (1) | FR20C1022I2 (ar) |
HK (1) | HK1159524A1 (ar) |
HR (1) | HRP20150567T1 (ar) |
HU (2) | HUE026400T2 (ar) |
IL (2) | IL294658A (ar) |
JO (1) | JO3044B1 (ar) |
LT (1) | LTC2379069I2 (ar) |
LU (1) | LUC00160I2 (ar) |
MA (1) | MA32907B1 (ar) |
MX (2) | MX2011006625A (ar) |
NL (1) | NL301046I2 (ar) |
NO (1) | NO2020017I1 (ar) |
NZ (1) | NZ593427A (ar) |
PL (1) | PL2379069T3 (ar) |
PT (1) | PT2379069E (ar) |
RU (1) | RU2561681C2 (ar) |
SG (1) | SG171888A1 (ar) |
SI (1) | SI2379069T1 (ar) |
TN (1) | TN2011000281A1 (ar) |
TW (1) | TWI472327B (ar) |
UY (1) | UY32350A (ar) |
WO (1) | WO2010072703A1 (ar) |
ZA (1) | ZA201104102B (ar) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
JP5878015B2 (ja) * | 2008-07-23 | 2016-03-08 | ノバルティス アーゲー | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 |
EA201100978A1 (ru) | 2008-12-22 | 2012-01-30 | Новартис Аг | Схема приема агониста рецептора s1p |
CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
WO2011138398A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
JO3619B1 (ar) | 2011-01-07 | 2020-08-27 | Novartis Ag | صياغات مثبطة للمناعة |
WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
WO2013057212A1 (en) * | 2011-10-21 | 2013-04-25 | Novartis Ag | Dosage regimen for an s1p receptor modulator or agonist |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
CA2900844C (en) * | 2013-04-04 | 2022-05-03 | Novartis Ag | Identifying patient response to s1p receptor modulator administration |
KR102466348B1 (ko) * | 2014-04-10 | 2022-11-10 | 노파르티스 아게 | 면역억제제 제제 |
EP3831378A1 (en) | 2014-04-10 | 2021-06-09 | Novartis AG | Siponimod immediate release dosage regimen for treating autoimmune diseases |
MY188764A (en) | 2014-12-11 | 2021-12-30 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
AU2016205361C1 (en) * | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
CA2973540A1 (en) * | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
AU2018341154A1 (en) * | 2017-09-29 | 2020-03-12 | Novartis Ag | Dosing regimen of siponimod |
MX2020007326A (es) * | 2017-09-29 | 2020-09-07 | Novartis Ag | Regimen de dosificacion de siponimod. |
IL292529A (en) | 2019-10-31 | 2022-06-01 | Idorsia Pharmaceuticals Ltd | Combination of cxcr7 antagonist with s1p1 receptor modulator |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
EP4288041A1 (en) | 2021-02-08 | 2023-12-13 | Bausch Health Ireland Limited | Amiselimod for preventing, treating, or ameliorating ulcerative colitis |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1176819A (zh) * | 1997-09-03 | 1998-03-25 | 王树生 | 一种解酒饮料及其制备方法 |
NZ560662A (en) | 2002-05-16 | 2009-09-25 | Novartis Ag | Use of EDG receptor binding agents in cancer |
TW200505442A (en) | 2003-05-19 | 2005-02-16 | Genomics Inst Of The Novartis Res Foundation | Immunosuppressant compounds and compositions |
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
SG147450A1 (en) * | 2003-10-29 | 2008-11-28 | Wyeth Corp | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
CN1913892A (zh) | 2003-12-17 | 2007-02-14 | 大日本住友制药株式会社 | 药物组合物及联合药物 |
UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
WO2005113330A1 (en) | 2004-05-05 | 2005-12-01 | Adler, Richard, S. | Systems and methods for protecting ship from attack on the surface or under water |
RU2478384C2 (ru) * | 2004-11-29 | 2013-04-10 | Новартис Аг | Курс лечения с использованием агониста рецептора s1p |
PL1931346T3 (pl) * | 2005-09-09 | 2013-01-31 | Angelini Labopharm Llc | Kompozycja trazodonu do podawania raz na dobę |
WO2008072056A1 (en) * | 2006-12-14 | 2008-06-19 | Pfizer Limited | Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation |
DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
BRPI0818161B8 (pt) * | 2007-10-12 | 2021-05-25 | Novartis Ag | mistura estável compreendendo agonista de receptores de s1p, sua forma de dosagem final e seu uso |
-
2009
- 2009-12-21 RU RU2011129856/15A patent/RU2561681C2/ru active
- 2009-12-21 IL IL294658A patent/IL294658A/en unknown
- 2009-12-21 MX MX2011006625A patent/MX2011006625A/es active IP Right Grant
- 2009-12-21 JO JOP/2009/0495A patent/JO3044B1/ar active
- 2009-12-21 HU HUE09793546A patent/HUE026400T2/en unknown
- 2009-12-21 KR KR1020117017072A patent/KR101660555B1/ko active IP Right Grant
- 2009-12-21 MX MX2015011590A patent/MX367667B/es unknown
- 2009-12-21 CN CN2009801519427A patent/CN102264363A/zh active Pending
- 2009-12-21 AR ARP090105009A patent/AR074825A1/es unknown
- 2009-12-21 PL PL09793546T patent/PL2379069T3/pl unknown
- 2009-12-21 DK DK09793546.4T patent/DK2379069T3/en active
- 2009-12-21 AU AU2009331582A patent/AU2009331582B2/en active Active
- 2009-12-21 JP JP2011541496A patent/JP5657565B2/ja active Active
- 2009-12-21 ES ES09793546.4T patent/ES2538413T3/es active Active
- 2009-12-21 SI SI200931199T patent/SI2379069T1/sl unknown
- 2009-12-21 WO PCT/EP2009/067618 patent/WO2010072703A1/en active Application Filing
- 2009-12-21 CA CA3105857A patent/CA3105857C/en active Active
- 2009-12-21 UY UY0001032350A patent/UY32350A/es not_active Application Discontinuation
- 2009-12-21 BR BRPI0923213A patent/BRPI0923213A2/pt not_active IP Right Cessation
- 2009-12-21 TW TW98143961A patent/TWI472327B/zh active
- 2009-12-21 NZ NZ593427A patent/NZ593427A/xx not_active IP Right Cessation
- 2009-12-21 EP EP09793546.4A patent/EP2379069B1/en active Active
- 2009-12-21 CN CN201510541635.7A patent/CN105213372A/zh active Pending
- 2009-12-21 CA CA2747992A patent/CA2747992C/en active Active
- 2009-12-21 SG SG2011039765A patent/SG171888A1/en unknown
- 2009-12-21 PT PT97935464T patent/PT2379069E/pt unknown
- 2009-12-21 CA CA2981830A patent/CA2981830A1/en not_active Abandoned
- 2009-12-22 US US12/655,049 patent/US8492441B2/en active Active
-
2011
- 2011-05-31 TN TN2011000281A patent/TN2011000281A1/fr unknown
- 2011-06-02 ZA ZA2011/04102A patent/ZA201104102B/en unknown
- 2011-06-02 IL IL21334711A patent/IL213347B/en active IP Right Grant
- 2011-06-17 MA MA33953A patent/MA32907B1/ar unknown
-
2012
- 2012-01-10 HK HK12100257.4A patent/HK1159524A1/xx unknown
-
2013
- 2013-06-18 US US13/920,406 patent/US20130281712A1/en active Pending
-
2014
- 2014-09-19 JP JP2014191541A patent/JP5941110B2/ja active Active
-
2015
- 2015-05-27 HR HRP20150567TT patent/HRP20150567T1/hr unknown
- 2015-05-27 CY CY20151100469T patent/CY1116321T1/el unknown
-
2020
- 2020-06-16 NL NL301046C patent/NL301046I2/nl unknown
- 2020-06-17 NO NO2020017C patent/NO2020017I1/no unknown
- 2020-06-17 HU HUS2000017C patent/HUS2000017I1/hu unknown
- 2020-06-18 LU LU00160C patent/LUC00160I2/fr unknown
- 2020-06-18 FR FR20C1022C patent/FR20C1022I2/fr active Active
- 2020-06-19 CY CY2020014C patent/CY2020014I2/el unknown
- 2020-06-23 LT LTPA2020513C patent/LTC2379069I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3044B1 (ar) | نظام تناول جرعة لمنبه مستقبل s1p | |
MX2021010759A (es) | Regimen de dosificacion para un agonista de los receptores de s1p. | |
PH12017501495A1 (en) | Dosage regimen of an s1p receptor modulator | |
MX2012000704A (es) | Agonistas de gpr119. | |
MX366325B (es) | Terapia de combinacion. | |
EA201190021A1 (ru) | Модуляторы toll-подобных рецепторов | |
MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
TNSN07209A1 (en) | Dosage regimen of an s1p receptor agonist | |
MX2013007622A (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
MX2007010752A (es) | Usos oftalmicos de moduladores de receptor s1p. | |
TW200738269A (en) | Oral delivery of therapeutic agents using tight junction agonists | |
CU20130155A7 (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
MX2012012245A (es) | Combinacion de una reabsorcion de inhibidor de serotonina y norepirefrina y un agonista opioide para el tratamiento del dolor. | |
UA106219C2 (ru) | Модуляторы толл-подобных рецепторов |